Analysis Of The Efficacy Of Infliximab Therapy On Crohn’s Disease

Part ⅠObjective: To investigate the efficacy and safty of infliximabtherapy for Crohn’s disease.Methods:24patients with Crohn’s disease(CD) who were fromShanghai Renji Hospital accepted infliximab therapy from January2011toOctober2013were included. Infliximab induction was administered atweeks0,2, and6and maintenance therapy at8-week intervals till30weeks. The efficacies of therapy by infliximab (5mg/kg intravenousinfusion) after6weeks and30weeks were observed respectively andcompared.Results: After6weeks therapy by infliximab, the clinical symptomsand blood indexes of the patients were significantly improved, and after30weeks the efficacies showed further improved comparing that of after6weeks treatment.Conclusion: Infliximab therapy was proved to be effective and safe inthe treatment of CD, and the efficacies after30weeks therapy showedfurther improved comparing that of6weeks therapy.Part ⅡObjective: To evaluate the efficacy and safety of monotherapyof infliximab compared with combination therapy of infliximab andimmunosuppressives on patients with CD.Methods:24patients with CD from Shanghai Renji Hospital fromJanuary2011to October2013were included. They were divided into2groups. In one group the patients were accepted monotherapy of infliximab.In the another group the patients were accepted combination therapy ofinfliximab and azathioprine at the same time(this group plus azathioprine 1-2mg/kg/d from the sixth week). The efficacies of monotherapy andcombination therapy after6weeks and30weeks were observedrespectively and compared.Results: No significant differences of clinical symptoms and bloodindex were observed at the30th week between the two groups.Conclusion: The difference of the efficacies between infliximabmonotherapy and combination therapy with infliximab and azathioprine inCD need further clinical follow-up.Part Ⅲ Objective: To compare the efficacy of step-up infliximabtherapy and step-down Infliximab therapy in patients with Crohn’s disease.Methods:12patients with CD from Shanghai Renji Hospital fromJanuary2011to October2013who accepted infliximab therapy in earlystage of the disease and9cases accepted infliximab therapy after theirtraditional treatment failure were included and divided into two groups.Compare the efficacies of the step-up therapy and Top-down therapy in thetwo groups.Results: No significant differences were observed in the clinicalsymptoms and blood index between the two groups with step-upInfliximab therapy and step-down Infliximab therapy respectively.Conclusion: Larger clinical trials with longer follow-up are warrantedto further assess the efficacy and safety profile of step-up and Top-downtherapy.